2334 GMT - Wider adoption of Pro Medicus's medical-imaging tech looks inevitable to its bulls at Goldman Sachs. Calling Pro Medicus one of Australia's best global growth companies, GS analysts write in a note that they expect a strong increase in the cadence and value of contract wins over time. Adoption is a matter of when, not if, they reckon. The analysts think that there is potential for material upside from outsized contracts worth more than A$100 million, but they acknowledge that visibility here is limited in terms of both size and timing. GS lifts its target price 26% to A$278.00 and keeps a buy rating on the stock. Shares are up 3.7% at A$256.29. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
December 11, 2024 18:34 ET (23:34 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.